Great insight Istari, thanks for sharing. I have recently...

Great insight Istari, thanks for sharing. I have recently witnessed the likes of Taylor selling out of $8CO and it was brutal, the price was pushed down to 6c but then recovered and hit over 10c. When you combine this sort of broker selling between Shaw/Taylor with retail fear, the result is a quick decline which appears to have occurred here. The good news is that usually the recovery is just as quick where the company's fundamentals remain intact.

When you compare the potential of the new Mobvoi/CardieX smart watch to other biotechs/healthcare companies on the market with a niche clientele, the value and opportunity here is non-comparable. Cardiovascular disease is the number one killer across the globe and this smart watch will be the first of its kind to feature arterial age (arterial disease is the most common heart disease), exercise capacity and heart stress.

An exciting point to keep in mind is that this technology can be integrated around multiple disorders, specifically those related to vascular disease such as Alzheimer's. To that end, iRhythm (mentioned below) plays a vital role to monitor irregular heart rhythm which is linked to an increase risk of Alzheimer's. I'm certainly looking forward to see what CardieX develops in this space.





From a revenue perspective, it includes subscription fees and product sales based on direct to consumer sales and distribution rights. The product launch will be early 2021 which tells me design etc is ready to go and manufacturing to begin soon. Keeping in mind Mobvoi is a billion dollar company and backed by Google (who own fitbit)

One can only assume that talks have begun with the likes of Apple and Samsung to include these world first heart health features.




Good luck all, the above is only one arm of the companies business which speaks to the value and opportunity at play.